Long-term progression-free survival of patients with metastatic melanoma or renal cell carcinoma following high-dose interleukin-2.
Clark JI, Curti B, Davis EJ, Kaufman H, Amin A, Alva A, Logan TF, Hauke R, Miletello GP, Vaishampayan U, Johnson DB, White RL, Wiernik PH, Dutcher JP.
Clark JI, et al. Among authors: amin a.
J Investig Med. 2021 Feb 4;69(4):888-92. doi: 10.1136/jim-2020-001650. Online ahead of print.
J Investig Med. 2021.
PMID: 33542072
Free PMC article.